Boston, Massachusetts Clinical Trials

A listing of Boston, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 111 clinical trials
TDCS to Improve Motivation and Memory in Elderly (TIME)

Fundamental advancements in understanding successful aging are limited by the lack of causal, rather than just correlational methods to connect age-related changes in memory ability to changes in brain structure and function. In this study, non-invasive electric brain stimulation will be used as a tool to create causal links between …

Northeastern University
 (1.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

measurable disease
growth factor
serum pregnancy test
myd88 gene mutation
absolute neutrophil count
Massachusetts General Hospital
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

The objective of this study is to conduct a pilot, randomized sham-controlled trials to determine the feasibility and effects of a 10-session personalized tDCS intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in 24 older adults with mild …

transcranial direct current stimulation
alzheimer's disease
tics
mild cognitive impairment
brain stimulation
Hebrew Rehabilitation Center
 (5.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

neurofibroma
measurable disease
multiple meningiomas
crizotinib
schwartz
Children's Hospital Boston (Site 725)
 (1.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

HER2
erbb1
stage iv breast cancer
epidermal growth factor receptor
breast cancer
Massachusetts General Hospital
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

ki-ras
kras
solid tumour
metastatic malignant solid tumor
kras g12c mutation
Dana Farber Cancer Institute
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

immunohistochemistry
serum bilirubin level
sentinel lymph node biopsy
breast irradiation
immunomodulators
Dana-Farber Cancer Institute
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

triamcinolone
clindamycin
malignant glioma
topical agents
glioma
Tufts Medical Center
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

measurable disease
carcinoma
squamous cell carcinoma
cytotoxic chemotherapy
conjugated bilirubin
Massachusetts General Hospital Cancer Center
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Preoperative Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF). Right ventricular dysfunction and failure after LVAD implantation is known to increase morbidity and mortality and contribute to longer post-implant hospital length of stay. Since RVF is difficult to predict and can …

right ventricular failure
ventricular dysfunction
Massachusetts General Hospital
 (0.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location